Patents by Inventor Peter James Watts
Peter James Watts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9814705Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: June 23, 2015Date of Patent: November 14, 2017Assignee: Depomed, Inc.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Publication number: 20150283123Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: ApplicationFiled: June 23, 2015Publication date: October 8, 2015Inventors: Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
-
Patent number: 9078814Abstract: An intrasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: July 3, 2012Date of Patent: July 14, 2015Assignee: DEPOMED, INC.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Patent number: 8946208Abstract: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100% by volume of N-methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).Type: GrantFiled: August 29, 2008Date of Patent: February 3, 2015Assignee: Archimedes Development LimitedInventors: Jonathan Castile, Alan Smith, Yu-Hui Cheng, Peter James Watts
-
Patent number: 8889176Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: July 3, 2012Date of Patent: November 18, 2014Assignee: Depomed, Inc.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Lafferty, Alan Smith
-
Patent number: 8710028Abstract: A powder composition for intranasal delivery includes a benzodiazepine drug and chitosan, a salt of chitosan, a derivative of chitosan or a salt of a derivative of chitosan.Type: GrantFiled: August 29, 2008Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Peter James Watts, Yu-Hui Cheng, Alan Smith, Jonathan Castile
-
Patent number: 8481070Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: GrantFiled: September 30, 2009Date of Patent: July 9, 2013Assignee: Archimedes Development LimitedInventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
-
Publication number: 20120277267Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: ApplicationFiled: July 3, 2012Publication date: November 1, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
-
Publication number: 20120270903Abstract: An intranasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
-
Patent number: 8216604Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: March 13, 2008Date of Patent: July 10, 2012Assignee: Archimedes Development LimitedInventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Patent number: 8034371Abstract: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.Type: GrantFiled: December 23, 2004Date of Patent: October 11, 2011Assignee: Archimedes Development LimitedInventors: Jonathan David Castile, Yu-Hui Cheng, Paul George Jenkins, Alan Smith, Peter James Watts
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Patent number: 7947257Abstract: Compositions are provided for the intranasal administration of granisetron or a pharmaceutically acceptable salt thereof. Preferred compositions are in the form of an aqueous solution. Optionally, the compositions comprise chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention of nausea and/or vomiting.Type: GrantFiled: December 3, 2004Date of Patent: May 24, 2011Assignee: Archimedes Development LimitedInventors: Peter James Watts, Alan Smith, Jonathan Castile
-
Publication number: 20110105551Abstract: An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.Type: ApplicationFiled: January 12, 2011Publication date: May 5, 2011Applicants: Vernalis (R&D) Limited, Archimedes Development CorporationInventors: Phillip John Birch, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
-
Publication number: 20100256091Abstract: A powder composition for intranasal delivery includes a benzodiazepine drug and chitosan, a salt of chitosan, a derivative of chitosan or a salt of a derivative of chitosan.Type: ApplicationFiled: August 29, 2008Publication date: October 7, 2010Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James Watts, Yu-Hui Cheng, Alan Smith, Jonathan Castile
-
Patent number: 7666876Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.Type: GrantFiled: March 19, 2002Date of Patent: February 23, 2010Assignees: Vernalis (R&D) Limited, Archimedes Development LimitedInventors: Phillip John Birch, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
-
Publication number: 20100041624Abstract: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.Type: ApplicationFiled: October 19, 2009Publication date: February 18, 2010Applicants: VERNALIS (R&D) LIMITED, ARCHIMEDES DEVELOPMENT LIMITEDInventors: Phillip John Brich, Ann Gail Hayes, Peter James Watts, Jonathan David Castile
-
Patent number: 7662403Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: GrantFiled: January 4, 2006Date of Patent: February 16, 2010Assignee: Archimedes Development LimitedInventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
-
Publication number: 20100021553Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: ApplicationFiled: September 30, 2009Publication date: January 28, 2010Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Ann Margaret DYER, Peter James WATTS, Yu-Hui CHENG, Alan SMITH
-
Publication number: 20090233912Abstract: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100% by volume of N-methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).Type: ApplicationFiled: August 29, 2008Publication date: September 17, 2009Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Jonathan CASTILE, Alan SMITH, Yu-Hui CHENG, Peter James WATTS